Trinity Eye Institute-B (06622): Mexarone obtained orphan drug qualification certification from the US FDA for the treatment of retinoblastoma in children.

News from the Wisdom Finance APP, Zoom Vision-B (06622) announced that the U.S. Food and Drug Administration (FDA) has granted the company's patented formula, used to treat retinoblastoma (RB), a rare type of childhood eye cancer, orphan drug designation (ODD).